Compare KB Financial Group, Inc. (KB) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KB Financial Group, Inc. vs Neurocrine Biosciences Inc — how do they compare? KB Financial Group, Inc. trades at $120.1 (market cap $38.56B), while Neurocrine Biosciences Inc trades at $178.4 (market cap $17.40B). The key difference: KB Financial Group, Inc. is far larger — about 2.2× Neurocrine Biosciences Inc's market cap, and KB Financial Group, Inc. pays a 2.72% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| KB | NBIX | |
|---|---|---|
Market Cap | $38.56B | $17.40B |
Sector | Financials | Health |
52-Week High | $123.25 | $180.55 |
52-Week Low | $77.50 | $123.10 |
Dividend Yield | 2.72% | — |
Enterprise Value | — | $16.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KB Financial Group (KB) trades at $115.23, down 3.47% today, but maintains a bullish technical outlook with strong moving average signals. The company shows solid fundamental performance with a 27.82% net income margin and consistent earnings beats in recent quarters. Revenue growth has been steady, reaching $21.23T in 2025, while analyst sentiment is mixed with a 33.33% buy rating amid broader hold consensus. Recent news highlights diversification into non-banking segments, which now contribute 43% of earnings.
The stock presents a balanced outlook with upside from earnings growth and diversification efforts, but faces risks from volatile cash flows and macroeconomic pressures. Investors should weigh the attractive valuation metrics against execution risks in non-banking expansion. The current price near recent highs suggests cautious optimism is warranted.
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% with strong bullish momentum. Recent earnings beats, including Q1 2026 EPS of $1.94 versus $1.22 expected, underscore robust growth. The stock shows bullish technical signals with support at $170 and resistance at $173. Revenue growth accelerated to $2.86 billion in 2025, with net income margin improving to 21.55% in 2026 projections. Positive news highlights pipeline advancements and the Soleno acquisition.
Outlook remains positive with a consensus price target of $196.08, implying 13% upside. Key opportunities include sustained earnings growth and pipeline expansion, while risks involve clinical trial outcomes and competitive pressures. Institutional sentiment is strongly bullish with 86% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
